Akynzeo Side Effects

Generic name: netupitant / palonosetron

Medically reviewed by Drugs.com. Last updated on Jul 25, 2024.

Note: This document provides detailed information about Akynzeo Side Effects associated with netupitant / palonosetron. Some dosage forms listed on this page may not apply specifically to the brand name Akynzeo.

Applies to netupitant / palonosetron: oral capsule.

Common side effects of Akynzeo

Some side effects of netupitant / palonosetron may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common side effects

• headache
• fatigue
• unusual tiredness or weakness

Less common side effects

• constipation
• flushing or redness of the skin
• heartburn
• indigestion
• stomach discomfort, upset, or pain

Serious side effects of Akynzeo

Along with its needed effects, netupitant/palonosetron may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking netupitant / palonosetron:

Incidence not known

• agitation
• confusion
• dizziness
• fever
• hearing or seeing things that are not there
• muscle twitching
• overactive reflexes
• poor coordination
• shivering
• sweating
• trembling or shaking

For healthcare professionals

Applies to netupitant / palonosetron: oral capsule.

Gastrointestinal adverse events

• Common (1% to 10%): Constipation, dyspepsia
• Uncommon (0.1% to 1%): Abdominal distention, abdominal pain, diarrhea, flatulence, nausea
• Rare (0.01% to 0.1%): Dysphagia, tongue coated

Palonosetron:

• Common (1% to 10%): Constipation, dyspepsia^[Ref]

Nervous system

• Common (1% to 10%): Headache
• Uncommon (0.1% to 1%): Dizziness, vertigo
• Rare (0.01% to 0.1%): Abnormal taste, hypoesthesia

Palonosetron:

• Common (1% to 10%): Headache^[Ref]

Dermatologic

• Common (1% to 10%): Erythema
• Uncommon (0.1% to 1%): Alopecia, urticaria

Palonosetron:

• Common (1% to 10%): Erythema^[Ref]

Psychiatric

• Uncommon (0.1% to 1%): Insomnia
• Rare (0.01% to 0.1%): Acute psychosis, altered mood, sleep disorder

Palonosetron:

• Common (1% to 10%): Asthenia, fatigue^[Ref]

Other

• Common (1% to 10%): Asthenia, fatigue
• Rare (0.01% to 0.1%): Feeling hot

Palonosetron:

• Uncommon (0.1% to 1%): Fatigue^[Ref]

Cardiovascular

• Uncommon (0.1% to 1%): Atrioventricular (AV) block, AV block first degree, bundle branch block, cardiomyopathy, conduction disorder, electrocardiogram QT prolonged, hypertension
• Rare (0.01% to 0.1%): Arrhythmia, AV block second degree, electrocardiogram ST segment depression, electrocardiogram ST-T segment abnormal, hypotension, increased troponin, mitral valve incompetence, myocardial ischemia, ventricular extrasystoles

Palonosetron:

• Postmarketing reports: Shock^[Ref]

Hepatic

• Uncommon (0.1% to 1%): Elevated ALT, elevated AST, elevated total bilirubin, increased blood alkaline phosphatase
• Rare (0.01% to 0.1%): Increased blood bilirubin

Palonosetron:

• Uncommon (0.1% to 1%): Elevated AST, elevated ALT, elevated total bilirubin^[Ref]

Approximately 0.6% of patients given 0.5 mg of palonosetron developed AST greater than 3 times the upper limit of normal (ULN) and/or ALT greater than 3 x ULN with total bilirubin greater than ULN. Approximately 0.2% of patients given the same dose of palonosetron developed AST greater than 10 x ULN and/or ALT greater than 10 x ULN with total bilirubin greater than ULN, and approximately 0.1% of patients developed AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than or equal to 2 x ULN.

Approximately 0.3% of patients given oral formulations of netupitant-palonosetron developed AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than ULN, and AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than or equal to 2 x ULN occurred in up to 0.1% of patients.^[Ref]

Hematologic

• Uncommon (0.1% to 1%): Leukocytosis, neutropenia
• Rare (0.01% to 0.1%): Leukopenia, lymphocytosis^[Ref]

Musculoskeletal

• Uncommon (0.1% to 1%): Increased blood creatine phosphokinase
• Rare (0.01% to 0.1%): Back pain, non-cardiac chest pain

Palonosetron:

• Uncommon (0.1% to 1%): Myalgia^[Ref]

Ocular

• Rare (0.01% to 0.1%): Blurred vision, conjunctivitis

Palonosetron:

• Uncommon (0.1% to 1%): Eye swelling^[Ref]

Metabolic

• Uncommon (0.1% to 1%): Decreased appetite
• Rare (0.01% to 0.1%): Hypokalemia^[Ref]

Renal

• Uncommon (0.1% to 1%): Increased blood creatinine
• Rare (0.01% to 0.1%): Cystitis^[Ref]

Respiratory

• Uncommon (0.1% to 1%): Hiccups

Palonosetron:

• Frequency not reported: Dyspnea^[Ref]

Hypersensitivity

Palonosetron:

• Postmarketing reports: Anaphylactic/anaphylactoid reactions, anaphylaxis^[Ref]

Frequently asked questions

• What is the difference between the oral and injectable formulations of Akynzeo?

Further information

Akynzeo side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer